Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Till

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
American Journal of Hematology|May 7, 2019
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapyVictor A Chow, Ajay K Gopal, David G Maloney, et al.
Molecular Cancer Therapeutics|October 21, 2020
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTAJohnnie J Orozco, Aimee L Kenoyer, Yukang Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2015
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete RemissionAndrew J Cowan, Philip A Stevenson, Ryan D Cassaday, et al.
Transplantation and Cellular Therapy|August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell TherapySai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Blood|January 29, 2015
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse modelDamian J Green, Mazyar Shadman, Jon C Jones, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
American Journal of Hematology|May 7, 2019
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapyVictor A Chow, Ajay K Gopal, David G Maloney, et al.
Molecular Cancer Therapeutics|October 21, 2020
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTAJohnnie J Orozco, Aimee L Kenoyer, Yukang Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2015
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete RemissionAndrew J Cowan, Philip A Stevenson, Ryan D Cassaday, et al.
Transplantation and Cellular Therapy|August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell TherapySai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Blood|January 29, 2015
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse modelDamian J Green, Mazyar Shadman, Jon C Jones, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Pageof 12